B.Pharm Healthcare Psychology and Communication Skills Important Questions PDF 

Healthcare Psychology and Communication Skills – BP103T UNIT-WISE Important Questions, B.Pharma 1st Semester.

Unit – 1

1. Very Short Answers Questions

★Q1. Define the term “Psychology” with reference to its Greek etymological origin.
★Q2. Who formulated the Biopsychosocial (BPS) Model of healthcare and in which year?
Q3. State the average medication adherence rate reported by the World Health Organization (WHO, 2003) for long-term chronic therapies.
★Q4. What neurochemical pathways are primarily implicated in mediating the Placebo effect and the Nocebo effect?
Q5. State Weber’s Law of psychophysics and write its mathematical equation.

Q6. What is “Tall-Man Lettering” and why is it employed in pharmaceutical packaging and dispensing?
★Q7. Name the two calculation and spelling exercises used in the Mini-Mental State Examination (MMSE) to evaluate patient attention.
Q8. Differentiate between Positive Reinforcement and Negative Reinforcement in operant conditioning.
Q9. Define Albert Bandura’s concept of “Self-Efficacy” in the context of health behavior change.
Q10. State the historical immediate-memory capacity limit proposed by Miller’s Law.
Q11. Enlist the four developmental stages formulated in Jean Piaget’s Theory of Cognitive Development.
Q12. What does the counseling acronym “O-A-R-S” represent in Motivational Interviewing?

2. Short Answer Questions

★Q1. Differentiate between the traditional Biomedical Model and the modern Biopsychosocial (BPS) Model of healthcare.
★Q2. Explain the Gate Control Theory of Pain proposed by Melzack and Wall with its clinical significance in pharmacy.
Q3. Outline the clinical role of Clinical Psychology in monitoring adverse drug reactions (ADRs) such as Extrapyramidal Symptoms and Serotonin Syndrome.
★Q4. Describe the Health Belief Model (HBM) and list its six core cognitive constructs predicting patient health actions.
Q5. Explain how Ivan Pavlov’s Classical Conditioning accounts for Anticipatory Nausea and Vomiting (ANV) in cancer chemotherapy.

Q6. Enlist the four clinical varieties of attention and highlight their importance in preventing dispensing errors in community pharmacy.
Q7. Differentiate between Bottom-Up (Data-Driven) and Top-Down (Concept-Driven) perceptual processing with clinical examples.
★Q8. Describe B.F. Skinner’s Operant Conditioning matrix, providing one concrete healthcare example for each of the four quadrants.
Q9. Explain the Atkinson-Shiffrin Multi-Store Model of human memory architecture (Sensory, Short-Term, and Long-Term).
Q10. Describe the practical application of the “Teach-Back” method and “Chunking” in improving patient medication recall.
Q11. Contrast the James-Lange Theory and Cannon-Bard Theory of emotion using a clinical patient scenario.
Q12. Outline the “R-U-L-E” guiding framework of Motivational Interviewing practiced by clinical pharmacists.

3. Long Answer Questions

★Q1. Define healthcare psychology and discuss in detail its scope, clinical relevance, and the paradigm shift from the reductionist Biomedical Model to Dr. George Engel’s Biopsychosocial Model in pharmacy practice.
★Q2. Describe the four major branches of psychology having direct healthcare relevance (Clinical, Health, Behavioural, and Developmental Psychology), emphasizing their practical clinical applications across the human lifespan.
★Q3. Critically evaluate the cognitive triad of Sensation, Perception, and Attention in clinical assessment, covering sensory thresholds, psychophysical laws, Gestalt principles in LASA drug labeling, and cognitive screening tools.
Q4. Elaborate on the core theories of Learning and Human Memory Architecture in promoting health behavior change, discussing Pavlovian conditioning in chemotherapy, Skinner’s operant reinforcement, Bandura’s self-efficacy, and memory retrieval aids.
Q5. Detail the neurobiology and classical theories of Emotion (James-Lange, Cannon-Bard, Schachter-Singer, and Lazarus) and discuss Abraham Maslow’s Hierarchy of Human Needs in prioritizing chronic disease patient adherence.
Q6. Explain Prochaska and DiClemente’s Transtheoretical Model (Stages of Change) and evaluate how Motivational Interviewing (RULE principles and OARS micro-skills) resolves patient ambivalence and medication non-compliance.

Unit – 2

1. Very Short Answers Questions

★Q1. Name the psychosocial crisis identified by Erik Erikson for the infancy stage (birth to 1.5 years).
★Q2. What clinical criteria or guidelines should pharmacists audit to identify potentially inappropriate medications in geriatric patients?
Q3. State the fundamental conceptual distinction between “Disease” and “Illness” in healthcare psychology.
★Q4. Enlist the five personality dimensions comprising the Five-Factor Model (The Big Five / OCEAN).
Q5. State the two behavioral traits that define a Type D (Distressed) personality.

Q6. Which psychological defense mechanism is demonstrated when a hypertensive patient insists they are completely healthy and stops medication?
★Q7. Name the five cognitive dimensions of illness representation formulated in Leventhal’s Common-Sense Model (CSM).
Q8. Which neurochemical pathway is primarily responsible for mediating analgesia in the Placebo effect?
Q9. State the minimum duration of excessive, uncontrollable worry required by DSM-5 criteria to diagnose Generalized Anxiety Disorder (GAD).
★Q10. What critical FDA Black Box warning is mandated for all antidepressant medications prescribed to children, adolescents, and young adults?
Q11. Name the primary glucocorticoid hormone secreted by the adrenal cortex in the Hypothalamic-Pituitary-Adrenal (HPA) stress axis.
Q12. What relaxation technique developed by Edmund Jacobson involves systematically tensing and relaxing specific skeletal muscle groups?

2. Short Answer Questions

★Q1. Explain Erik Erikson’s psychosocial crisis of “Autonomy vs. Shame and Doubt” and its implications for toddler medication administration.
★Q2. Discuss age-related pharmacokinetic alterations (ADME) in geriatric patients and their clinical relevance in dosing.
Q3. Differentiate between Type A and Type B personality traits and their relevance to cardiovascular risk and patient communication.
Q4. Explain the four psychodynamic defense mechanisms (Denial, Regression, Projection, Rationalization) commonly encountered in healthcare.
★Q5. Describe the four healthcare communication approaches, explaining why Shared Decision-Making is considered the gold standard.

Q6. Differentiate between Internal and External Locus of Control according to Julian Rotter and their influence on therapy adherence.
Q7. Explain the neurobiology of the Nocebo effect and describe how pharmacists should positively frame adverse drug reactions.
★Q8. Outline the clinical presentation of Generalized Anxiety Disorder (GAD) and highlight the risks of chronic Benzodiazepine therapy.
Q9. Describe Serotonin Syndrome, including its clinical symptoms and dangerous drug-drug combinations.
Q10. Explain Somatization (Somatic Symptom Disorder) and formulate a pharmacist counseling strategy to prevent analgesic overuse.
★Q11. Contrast Problem-Focused Coping and Emotion-Focused Coping formulated by Lazarus and Folkman, citing adaptive healthcare examples.
Q12. Describe the “5 C’s” framework of psychological resilience in patients coping with chronic illnesses.

3. Long Answer Questions

★Q1. Detail Erik Erikson’s 8 stages of psychosocial development across the human lifespan, discussing the psychosocial crisis, primary healthcare needs, and targeted pharmacist interventions for each stage.
★Q2. Describe the Five-Factor Model (The Big Five / OCEAN) and personality typologies (Type A, B, C, D), explaining how each profile influences treatment adherence and patient interaction styles in pharmacy practice.
★Q3. Critically analyze Leventhal’s Common-Sense Model of Self-Regulation and the Health Belief Model (HBM), discussing how cognitive illness representations govern patient adherence in chronic non-communicable diseases.
Q4. Provide a comprehensive clinical account of Anxiety Disorders, Major Depressive Disorder (MDD), and Somatization, covering neurobiology, diagnostic criteria, psychopharmacotherapy warnings, and pharmacist counseling.
★Q5. Detail the neurobiology of the human stress response comparing the fast Sympathomedullary (SAM) axis and slower Hypothalamic-Pituitary-Adrenal (HPA) axis, and elaborate on Lazarus and Folkman’s Cognitive Appraisal Theory.
Q6. Explain evidence-based stress management and relaxation techniques (CBT cognitive restructuring, Jacobson’s PMR, 4-7-8 breathing, MBSR, Biofeedback) and outline the pharmacist’s 5-step behavioral intervention protocol.

Unit – 3

1. Very Short Answers Questions

★Q1. Define “Health Communication” in the context of clinical pharmacy practice.
★Q2. Enlist the eight core elements comprising the healthcare communication process.
Q3. State the fundamental limitation of the Shannon-Weaver Linear Model when applied to patient counseling.
★Q4. What does the clinical acronym “SBAR” stand for in interprofessional healthcare handovers?
Q5. Define “Proxemics” as a non-verbal communication modality in pharmacy consultations.

Q6. Differentiate between Synchronous and Asynchronous Tele-pharmacy consultations.
★Q7. State the recommended normal vocal pacing (words per minute) for pharmacists during verbal patient counseling.
Q8. Define “Presbycusis” encountered as a sensory barrier in geriatric pharmacy practice.
Q9. State the “3-Second Rule” of strategic silence utilized during active listening.
Q10. Name the three questions comprising the U.S. Indian Health Service (IHS) “Three Prime Questions” framework.

2. Short Answer Questions

★Q1. Differentiate between Berlo’s SMCR Model and Barnlund’s Transactional Model of communication regarding live clinical counseling.
★Q2. Explain the SBAR framework used for interprofessional clinical communication with a suitable pharmacy handover example.
Q3. Compare Interpersonal, Group, Mass, and Telehealth Communication across audience scale, feedback speed, and pharmacy advantages.
★Q4. Classify clinical communication barriers into physical, psychological, physiological, and semantic categories with healthcare examples.
Q5. Describe Gerard Egan’s SOLER model of non-verbal attending during pharmacist-patient counseling.

Q6. Differentiate between Open-Ended, Closed-Ended, and Probing questions in clinical history-taking, giving one pharmacy example of each.
★Q7. Distinguish between Empathy, Sympathy, Apathy, and Pity in therapeutic patient interactions.
Q8. Describe the NURSE framework for expressing clinical empathy during patient emotional distress.
Q9. Explain the clinical significance of cultural competence and religious fasting (e.g., Ramadan or Navratri) in diabetic pharmacotherapy.
Q10. Explain the “Teach-Back” (“Show-Me”) method and the “Ask Me 3” tool in verifying patient health literacy.

3. Long Answer Questions

★Q1. Describe the continuous healthcare communication cycle by explaining all eight core elements, and critically evaluate the five major communication models applied in clinical pharmacy practice.
★Q2. Discuss the four primary types of communication in healthcare (Interpersonal, Group, Mass, and Telehealth / Telepharmacy), highlighting non-verbal modalities, interprofessional SBAR handovers, and legal safeguards.
★Q3. Provide a detailed classification of communication barriers in clinical settings, and outline evidence-based pharmacist strategies to eliminate physical, sensory, semantic, and socio-cultural barriers.
Q4. Elaborate on the core competencies of Active Listening, Clinical Questioning Techniques, and Empathy, detailing the SOLER model, the IHS Three Prime Questions, and the NURSE protocol.
Q5. Discuss Culturally Appropriate and Inclusive Communication in modern pharmacy, detailing the ETHNIC model, health literacy challenges, the Teach-Back technique, and tailored interventions for vulnerable patient populations.

Unit – 4

1. Very Short Answers Questions

★Q1. Define “Health Communication” as an active therapeutic intervention in pharmaceutical care.
★Q2. State the three open-ended questions comprising the U.S. Indian Health Service (IHS) patient counseling protocol.
Q3. Define “Triadic Communication” and state two clinical situations where it occurs in pharmacy practice.
★Q4. What does the clinical handover acronym “SBAR” stand for in multidisciplinary healthcare teams?
★Q5. Name the six sequential clinical steps comprising the SPIKES protocol for delivering bad news.

Q6. Enlist the five psychological reactions of the Kübler-Ross grief trajectory in healthcare settings.
Q7. State the four fundamental principles of biomedical ethics formulated by Beauchamp and Childress.
Q8. Differentiate between Implied Consent and Express Consent in clinical pharmacy procedures.
Q9. Enlist the four structural documentation components of a clinical pharmacist SOAP note.
Q10. What is a Clinical Decision Support System (CDSS) and how does tiered alerting prevent alert fatigue?

2. Short Answer Questions

★Q1. Explain the five steps of the AIDET framework used for structured patient medication counseling.
★Q2. Describe the SBAR interprofessional handover tool with an illustrative clinical pharmacy example.
Q3. Discuss the challenges and pharmacist responsibilities in Triadic Communication involving family caregivers.
★Q4. Detail the six steps of the SPIKES protocol for delivering bad news or critical ADR reports in pharmacy practice.
Q5. Describe the Kübler-Ross 5 Stages of Grief observed in patients receiving chronic or terminal medical diagnoses.

★Q6. Explain the CALM and LAST models along with physical safety standards for de-escalating angry patients.
Q7. Discuss the four biomedical ethical principles (Autonomy, Beneficence, Non-Maleficence, Justice) in pharmacy practice.
★Q8. Enlist the lawful exceptions where a pharmacist is legally permitted or required to disclose confidential health data.
Q9. Explain the PARQ framework for obtaining valid Informed Consent and differentiate it from Pediatric Assent.
Q10. Describe the SOAP note documentation architecture with an illustrative Drug Therapy Problem (DTP) case.
Q11. Outline the essential clinical sections and reconciliation checklist required in a hospital Discharge Medication Summary.
Q12. Differentiate between EMR, EHR, and CPOE, and explain how CDSS helps prevent dispensing and dosing errors.

3. Long Answer Questions

★Q1. Discuss patient-centered communication and clinical counseling frameworks (AIDET, IHS Three Prime Questions, PEARLS), and explain evidence-based pharmacist strategies to overcome physical, linguistic, psychological, and sensory barriers.
★Q2. Describe interprofessional healthcare communication using the SBAR framework and the DESC conflict resolution script, and discuss the management of Triadic Communication with caregivers across complex drug delivery devices.
★Q3. Comprehensively evaluate the delivery of difficult news and emotionally charged communication in pharmacy, detailing the SPIKES protocol, the NURSE empathy framework, Kübler-Ross stages of grief, and evidence-based de-escalation models.
★Q4. Detail the legal and ethical dimensions of health communication in pharmacy, covering the four biomedical ethical principles, statutory confidentiality frameworks, lawful disclosure exceptions, and the PARQ model of informed consent.
Q5. Elaborate on clinical healthcare documentation (SOAP note architecture, PvPI ADR reporting with Naranjo causality assessment) and analyze the role of digital health infrastructure (EHR, CPOE, CDSS alert fatigue, and telepharmacy modalities).

Unit – 5

1. Very Short Answers Questions

★Q1. Define “Health Psychology” and state its primary focus in physical health sciences.
★Q2. State the two social rights and two mandatory obligations of Talcott Parsons’ “Sick Role”.
Q3. Who formulated Suchman’s Stages of Illness Seeking and in which year?
★Q4. Name the six cognitive constructs comprising the Health Belief Model (HBM).
Q5. State the Greek etymological roots and clinical meaning of the term “Psychosomatic”.

★Q6. What are the primary catecholamine mediators released by the fast SAM stress axis?
Q7. Differentiate between Medication Adherence and Medication Compliance according to the WHO.
Q8. Name the three interacting nodes comprising Aaron Beck’s Cognitive Triangle in medication taking.
★Q9. Enlist the three operational action principles of the World Health Organization (WHO) Psychological First Aid (PFA) framework.
Q10. What does the term “Person-First Language” signify in mental health communication?

2. Short Answer Questions

★Q1. Compare the traditional Biomedical Model with George Engel’s Biopsychosocial Model in pharmaceutical care.
Q2. Explain Suchman’s Five Stages of Illness Seeking with corresponding pharmacist clinical interventions.
★Q3. Describe the Health Belief Model (HBM) and explain why adherence is often poor in asymptomatic chronic diseases like hypertension.
Q4. Differentiate between Intentional and Unintentional Medication Non-Adherence with two pharmacy examples of each.
★Q5. Contrast the fast SAM stress pathway with the slower HPA axis, detailing their respective neurotransmitter and hormonal mediators.

Q6. Explain the Gut-Brain Axis and describe how chronic mental stress contributes to Irritable Bowel Syndrome (IBS).
Q7. Describe three common cognitive distortions (Catastrophizing, All-or-Nothing Thinking, Emotional Reasoning) and how a pharmacist applies cognitive restructuring.
★Q8. Outline the five stages of change in Prochaska and DiClemente’s Transtheoretical Model (TTM) and the pharmacist’s role in addressing relapse.
Q9. Explain what Psychological First Aid (PFA) is, clarifying three misconceptions regarding what PFA is NOT.
Q10. Describe the CDC Crisis & Emergency Risk Communication (CERC) six foundational principles in pharmacy emergency operations.
★Q11. Distinguish between Public Stigma, Self (Internalized) Stigma, and Structural Stigma in psychiatric healthcare.
Q12. Outline the clinical importance of educating patients on the therapeutic lag (latency) of antidepressant medications.

3. Long Answer Questions

★Q1. Critically analyze Suchman’s Stages of Illness Seeking and the Health Belief Model (HBM), discussing their theoretical constructs and clinical applications in overcoming chronic disease medication non-adherence.
★Q2. Detail the neurobiology of the mind-body connection, comparing the SAM and HPA stress cascades, and explain the pathophysiological mechanisms of major psychosomatic disorders encountered in pharmacy practice.
★Q3. Discuss Cognitive Behavioural Therapy (CBT) and the Transtheoretical Model (Stages of Change) in optimizing treatment adherence, detailing cognitive restructuring, behavioral activation, and stage-matched counseling strategies.
Q4. Elaborate on Psychological First Aid (PFA) and Crisis Communication in healthcare, detailing the WHO Look-Listen-Link framework, Johns Hopkins RAPID model, and the CDC CERC principles during emergency drug recalls or disasters.
★Q5. Discuss Mental Health Promotion, the dimensions of psychiatric stigma, and comprehensive pharmacist communication strategies for stigma reduction (person-first language, normalization, and confidentiality).
Q6. Differentiate between Medication Compliance, Adherence, and Concordance, and discuss evidence-based behavioral interventions (Habit Stacking, Dosette systems, Decisional Balance) to resolve intentional and unintentional non-adherence.

📌 Questions marked with (★) represent high-frequency university exam as well as internal exam questions derived from PCI semester evaluation trends. Students must prioritize these questions for core concept clarity and good scoring in exam.